✦ LIBER ✦

Glycosidic Prodrugs of Highly Potent Bifunctional Duocarmycin Derivatives for Selective Treatment of Cancer

✍ Scribed by Prof. Dr. Lutz F. Tietze; Dr. J. Marian von Hof; Dipl.-Chem. Michael Müller; Dr. Birgit Krewer; Dr. Ingrid Schuberth

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 340 KB
Volume: 49
Category: Article
ISSN: 0044-8249
DOI: 10.1002/anie.201002502

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antitumor Agents: Development of Highly

Antitumor Agents: Development of Highly Potent Glycosidic Duocarmycin Analogues for Selective Cancer Therapy

✍ Lutz F. Tietze; Felix Major; Ingrid Schuberth 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB

Enantio- and Diastereoselective Synthesi

Enantio- and Diastereoselective Synthesis of Duocarmycine-Based Prodrugs for a Selective Treatment of Cancer by Epoxide Opening

✍ Lutz F. Tietze; Heiko J. Schuster; Sonja M. Hampel; Stephan Rühl; Roland Pfoh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 317 KB 👁 1 views

Proof of Principle in the Selective Trea

Proof of Principle in the Selective Treatment of Cancer by Antibody-Directed Enzyme Prodrug Therapy: The Development of a Highly Potent Prodrug

✍ Lutz F. Tietze; Tim Feuerstein; Anja Fecher; Frank Haunert; Olaf Panknin; Ulrich 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

Proof of Principle in the Selective Trea

Proof of Principle in the Selective Treatment of Cancer by Antibody-Directed Enzyme Prodrug Therapy: The Development of a Highly Potent Prodrug

✍ Lutz F. Tietze; Tim Feuerstein; Anja Fecher; Frank Haunert; Olaf Panknin; Ulrich 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

Asymmetric Synthesis and Biological Eval

Asymmetric Synthesis and Biological Evaluation of Glycosidic Prodrugs for a Selective Cancer Therapy

✍ Lutz F. Tietze; J. Marian von Hof; Birgit Krewer; Michael Müller; Felix Major; H 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 390 KB 👁 1 views

## Abstract A severe limitation in cancer therapy is the often insufficient differentiation between malign and benign tissue using known chemotherapeutics. One approach to decrease side effects is antibody‐directed enzyme prodrug therapy (ADEPT). We have developed new glycosidic prodrugs such as (−

Highly Selective Compounds for the Antib

Highly Selective Compounds for the Antibody-Directed Enzyme Prodrug Therapy of Cancer

✍ Lutz F. Tietze; Tim Feuerstein 📂 Article 📅 2003 🏛 John Wiley and Sons ⚖ 51 KB